Navigation Links
Newbridge Securities Corporation Forms BioVentures Division

Newbridge Expands its Presence in the Biotech Industry

FT. LAUDERDALE, Fla., Feb. 17 /PRNewswire/ -- Newbridge Securities Corporation ("Newbridge"), a full-service securities broker-dealer and investment bank, is proud to announce the formation of the Newbridge BioVentures Division ("NBV"). NBV is dedicated to providing investment banking services for the biotech industry and related investment opportunities for institutional and sophisticated individual investors.

We are pleased to announce Christopher Carra as the Managing Director of NBV. Mr. Carra has been a registered representative in the securities industry for over 16 years, primarily focused in the biotech sector. Mr. Carra has been involved in several private placements and initial public offerings for biotech companies, and is a founding member of NBV. Prior to joining Newbridge in 2005, Mr. Carra worked at several private-client focused firms, most recently Oppenheimer & Co., where he worked from 2000-2005 as a senior vice president.

Please visit the BioVentures website; it can be accessed through or

"We are extremely excited to add NBV as a focus to our already diversified suite of businesses," said Guy S. Amico, Newbridge's president. "In addition, having powerful advisors, such as Dr. David Sherris, Ph.D., on the Scientific Advisory board will lend top-level credibility and research to enhance our success rate for our Institutional and Private Client Group clients."

About Newbridge

Newbridge Securities Corporation provides full service securities brokerage and investment banking services to a broad based group of individuals and corporate clients. Comprised of a committed and experienced team of financial service professionals, we seek to empower our clients to build and preserve wealth by providing superior financial services and products.

For more information on NBV, contact Christopher Cara at 561.391.1220 (email at or visit our website at

SOURCE Newbridge Securities Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MINRAD Receives Notice That NYSE Alternext Intends to File Delisting Application With Securities and Exchange Commission
2. deCODE Sells Auction Rate Securities
3. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
4. Credit Suisse Repurchases Auction Rate Securities (ARS) From Rosetta Genomics
5. Isolagen to Present at the JMP Securities Healthcare Focus Conference
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at JMP Securities Conference
7. ARCA biopharma to Present at JMP Securities Healthcare Focus Conference
8. Horizon Therapeutics to Present at JMP Securities Healthcare Focus Conference
9. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
10. NxStage Medical to Present at JMP Securities Healthcare Focus Conference
11. Genomic Health to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
(Date:10/12/2015)... October 12, 2015 ... version for enriched online experience --> ... to print version for enriched online experience ... media alternative to print version for enriched online ... of scientific, technical and medical information products and services, ...
(Date:10/11/2015)... ... October 11, 2015 , ... Intelligent Implant Systems, LLC is ... multiple surgeries have been completed with this new posterior thoracolumbar spinal fusion system. ... Center of the Carolinas. The Revolution™ Spinal System pioneers a new approach ...
(Date:10/9/2015)... and ROCKVILLE, Md. ... ("ITI"), a privately-held biotechnology company developing next generation ... that it has entered into an exclusive worldwide ... products for the treatment or prevention of any ... of the agreement, Immunomic Therapeutics will receive an ...
(Date:10/8/2015)... ... October 08, 2015 , ... Researchers at the University of Washington (UW) ... providing a new tool to study how diseases like dementia, Alzheimer's, and brain tumors ... and Ruikang Wang of the UW Department of Bioengineering, today in the Journal ...
Breaking Biology Technology:
(Date:9/28/2015)... 28, 2015  The monitoring of vital signs, ... temperature, is an essential component of patient assessment. ... deterioration in a patient,s condition. However, in general ... typically taken during routine observation rounds only once ... deteriorates between these observation rounds, the warning signs ...
(Date:9/26/2015)... 2015  Results of a TactioRPM pilot project ... at the Stanford Medicine X Conference. In a ... Connected Health Devices and Pharmacogenomics", Roger Simard ... explain how senior patients equipped with connected health ... via the TactioRPM remote patient monitoring platform were ...
(Date:9/10/2015)... 2015 Report Details Emerging ... Opportunities and Revenue Prospects to Help You Stay ... especially new drug classes? Get the latest technological ... exclusive market data and industry knowledge, benefitting your ... opportunities and sales predictions. Visiongain,s new study ...
Breaking Biology News(10 mins):